PMVP - CRISPR Omeros among actionable SMID-cap biopharma for H2 2021 at BofA

AYDINOZON/iStock via Getty Images Bank of America has listed CRISPR Therapeutics ([[CRSP]] -0.7%), Omeros Corporation ([[OMER]] -4.4%), Kiniksa Pharma ([[KNSA]] -2.4%), and PMV Pharma ([[PMVP]] -0.6%) as actionable small and mid-cap biopharma companies with key updates in H2 2021.The analysts led by Geoff Meacham argue that CRISPR’s clinical program for sickle cell disease and beta-thalassemia “is already largely de-risked.” However, they expect further momentum for shares as the company reveals more data/filing plans.The firm also highlights the upcoming data readout from CRISPR’s CAR-T program expected in H2 2021. In 2021, the company expects to announce data from phase 1 trials for CAR-T candidates CTX130 and CTX110 in R/R B-cell malignancies and solid tumors/ hematologic malignancies, respectively.The analysts also point out, “Omeros is positioned for its first narsoplimab approval.” The marketing application filed by the company for FDA approval for narsoplimab in hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA or TA-TMA) has

For further details see:

CRISPR, Omeros among “actionable” SMID-cap biopharma for H2 2021 at BofA